|Day Low/High||3.98 / 4.20|
|52 Wk Low/High||2.15 / 5.78|
Two model portfolio names announced first-quarter earnings results overnight. Here's our take on each.
Here's what we'll be listening for when these two model portfolio names discuss earnings later today and tomorrow.
The first trading day of the month often has a seasonal upswing, but the market will likely decline again later in the week.
Three model portfolio names reported earnings results this week as the broad market took a slide.
This week, we added one name to the model portfolio and locked in a strong profit by closing out another position.
This week, we added to one model portfolio position and took some profits in two others.
An investment firm has initiated coverage with a buy rating on this model portfolio stock.
The model portfolio gained a new name this week as it followed the upward trend of financial and retail stocks.
News of a drug's approval or rejection from the FDA can rock or kill a biotech stock's price. Here are 14 companies with drugs facing FDA approval decisions in 2010.
A new name joined the model portfolio as the second quarter kicked off during this holiday-shortened week.
During an intriguing week for the markets, we focused on compiling a list of potential new names to add to the model portfolio.
This model portfolio position is trading higher amid rumors regarding a potential partnership for its obesity drug.
This week, we padded our position in one model portfolio name and took some profits in another.
We made some sales in the model portfolio this week, as the major market averages hit their highest levels in over a year.
This model portfolio biotech name reported fourth-quarter results that exceeded the consensus analyst estimates.
Though there is plenty of risk in the model, we believe the potential reward makes this stock attractively valued.
It was a volatile week for the model portfolio, as we navigated through a lot of earnings reports.
This model portfolio name is trading higher this morning on word that the FDA accepted its obesity drug application.
A busy week of positive earnings reports for the model portfolio names left us with an upbeat outlook for 2010.
Solid earnings results boosted the model portfolio this week, and we have more reports to look forward to next week.
Despite the volatile trading activity this week, we added shares to only one position in the model portfolio.
The market's volatility made for an extremely busy week for the model portfolio as we made adjustments to several holdings.
Taking advantage of the leg down in the broader market, we're upping our shares in this name.
A new stock joined the model portfolio this week and we used the increased volatility to build up two other names.
We used the volatility in the market this week to make several trades and add a new model portfolio position.
Using today's selloff to close out a Three-rated holding to fund additions to two of our other model portfolio names.
As earnings season began this week, we focused on researching some potential new names for the model portfolio.
This name is trading higher today after reporting strong phase III trial data for one its promising new drugs.
The J.P. Morgan Healthcare Conference kicks off with a flurry of biotech company updates.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.